Pfizer Archives

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 298Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 246Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

by John F. Heerdink, Jr. June 26, 2026 454Views 0Likes

Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…

Reverse Merger, Forward Thinking: InMed, Mentari and the Billion‑Patient Migraine Market -( $INM )

by John F. Heerdink, Jr. May 19, 2026 396Views 0Likes

InMed Pharmaceuticals’ (NASDAQ: INM) planned merger with Mentari Therapeutics reads less like a struggling micro-cap pivot and more like a biotech coming‑of‑age story set against a trillion‑dollar headache: migraine. If the deal closes as outlined, a once‑overlooked cannabinoid platform could become the…

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

by John F. Heerdink, Jr. May 16, 2026 458Views 0Likes

The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors. FDA’s New Cast at the Top The Food…

Family Offices Put On The White Coat: Why The Smart Money Is Suddenly Fluent In AI & Oncology

by John F. Heerdink, Jr. May 12, 2026 443Views 0Likes

Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other. Healthcare Becomes the New Family Office Heirloom After a cautious March tied to geopolitical jitters…

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

by John F. Heerdink, Jr. April 28, 2026 610Views 0Likes

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 323Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 485Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

The Billion-Dollar Hangover of Falling Vaccination Rates And Why GeoVax Brought the Coffee -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 9, 2026 429Views 0Likes

GeoVax Labs (NASDAQ: GOVX) sits at the intersection of a public health problem and a balance-sheet opportunity: falling vaccination rates are quietly inflating a future bill that taxpayers, hospitals and employers will all be forced to pay. As policymakers tally the hidden…

Pfizer

Your Guide To Staying Informed In The Markets